[The cardiovascular and thromboembolic complications of intravital estrogen therapy in middle-aged and elderly patients with prostatic cancer].
Cardiovascular and thromboembolic complications arising as a result of 1-16-year estrogen therapy were evaluated in 105 prostatic cancer patients. The incidence of the complications was higher in those who had pretreatment cardiological or vascular load. The latter caused death in half of the patients. Preventive and therapeutic measures to control the complications, prognosis signs are indicated.